Lundbeck Q3 2019 Financial Results

9M 2019 and FY 2018 - Product distribution of revenue DKKm FY 2018 FY 2017 9M 2019 9M 2018 Growth Growth in local currencies % of total TOTAL: Abilify Maintena 1,595 1,333 1,457 1,180 23% 21% 12% Brintellix/Trintellix 2,182 1,663 2,023 1,543 31% 28% 16% Cipralex/Lexapro 2,257 2,392 1,809 1,894 (4%) (5%) 14% Northera 1,806 1,644 1,606 1,282 25% 18% 13% Onfi 3,165 3,022 840 2,669 (69%) (70%) 7% Rexulti/Rxulti 1,723 1,247 1,620 1,204 35% 27% 13% Sabril 1,342 1,509 643 983 (35%) (39%) 5% Other pharmaceuticals 3,143 4,074 2,378 2,392 (1%) (2%) 19% Other revenue 662 402 433 466 (7%) (7%) 3% Effects from hedging 242 (52) (194) 308 (2%) Total revenue 18,117 17,234 12,615 13,921 (9%) (9%) 100% 56 Lundbeck

View entire presentation